Peptide-Hormone- And Serotonin-Immunoreactive Tumour Cells in Carcinoma of the Prostate

Abrahamsson, Per‐Anders; Wadström, Lars B.; Alumets, J.; Falkmer, Sture; Grimelius, Lars

doi:10.1016/s0344-0338(87)80065-1

Cited by 142 publications

(68 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of NE differentiation in PC is variable depending on the NE marker considered. 3,33 The existence of NE subpopulations producing specific substances is interesting since the secreted products could potentially have different effects on neighboring non-NE tumor cells. In the clinical material, we observed PAMP-like expression in 80% of tumors while PAM was present to a lesser extent.…”

Section: Discussionmentioning

confidence: 99%

“…Tumors were grown to a maximal volume of 2,000 mm. 3 For castration experiments, implants were removed and male mice castrated under Hypnorm anesthesia (Janssen, Oxford, UK). Mice were killed at short-term intervals after androgen ablation: days 0, 0.5, 1, 1.5, 2, 4, 7, 14 and 21 for PC-295 and days 0, 2, 5, 7, 14 and 21 for PC-310.…”

Section: Human Prostate Tumor Xenograft Modelsmentioning

confidence: 99%

“…2 In PC, the reported incidence of NE cells has increased as detection methods have improved. 3,4 The function of the NE population in the normal and malignant prostate remains unknown. Together with generic NE markers, such as CgA or CgB, 5 prostatic NE cells produce biogenic amines and neuropeptides.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Peptidylglycine ?-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate

Jiménez¹,

Jongsma²,

Calvo³

et al. 2001

Int. J. Cancer

View full text Add to dashboard Cite

Most PCs show NE differentiation. Several studies have tried to correlate NE expression with disease status, but the reported findings have been contradictory. Prostatic NE cells synthesize peptides with a wide spectrum of potential functions. Some of these active peptides, such as PAMP, are amidated. PAM is the only carboxy-terminal peptide-amidating enzyme identified. We studied expression of PAMP and PAM in normal prostate and prostatic tumors (clinical specimens and human xenograft models) with or without prior androgen-deprivation therapy and found a wide distribution of both molecules in NE subpopulations of all kinds. Although the correlation of either marker to tumor grade, clinical progression or disease prognosis did not reach statistical significance, PAMP-or PAM-immunoreactive cells were induced after androgen-blockade therapy. In the PC-310 and PC-295 androgen-dependent models, PAMP or PAM NE differentiation was induced after castration in different ways, being higher in PC-310, which might explain its long-term survival after androgen deprivation. We show induction of expression of 2 new NE markers in clinical specimens and xenografted PC after endocrine therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Human Prostate Tumor Xenograft Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Peptidylglycine ?-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate

Jiménez¹,

Jongsma²,

Calvo³

et al. 2001

Int. J. Cancer

View full text Add to dashboard Cite

show abstract

“…48,49 According to the latter definition, nearly all adenocarcinomas of the prostate demonstrate some degree of NE differentiation. 50 NE cancer cells, unlike non-NE, secretory-type cancer cells, do not express AR. 51 Consequently, although ADT induces apoptosis of the androgen-dependent, secretory-type cancer cells (which express AR), ADT actually may enrich for NE cancer cells, which appear to be postmitotic.…”

Section: Ne Differentiation In Hrpcmentioning

confidence: 90%

“…[65][66][67][68][69][70][71] In vitro, some NE cell products stimulate the proliferation of prostate cancer cells. 47,50,72 For instance, interleukin 8 (IL-8), which is an angiogenic and mitogenic factor for many tumors, promotes androgen-independent proliferation of prostate cancer cells in vitro. 73 Tissue studies similarly have demonstrated that NE cells in prostate cancer produce IL-8 and that non-NE tumor cells express increased levels of the IL-8 receptor, CXCR1, 74 suggesting that NE differentiation may be 1 of the factors that contribute to the progression of prostate cancer in a paracrine fashion.…”

Section: Ne Differentiation In Hrpcmentioning

confidence: 99%

Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

Tay

Huang

2006

Cancer

View full text Add to dashboard Cite

Docetaxel chemotherapy is the current standard of care for metastatic hormone-refractory prostate cancer (HRPC). Platinum chemotherapy drugs, such as cisplatin and carboplatin, have moderate single-agent activity in HRPC. Next-generation platinum drugs, including satraplatin and oxaliplatin, may have additional activity in the management of HRPC. Furthermore, neuroendocrine differentiation may play a role in disease progression, providing a rationale for platinum-based chemotherapy in the management of HRPC. The authors reviewed the MEDLINE database for reports related to platinum-based chemotherapy in patients with advanced prostate cancer and evaluated studies that reviewed the role of neuroendocrine differentiation in the progression of HRPC. Older studies from the 1970s and 1980s suggested a lack of activity of cisplatin and carboplatin; however, those studies were flawed at least in part by their methods of response assessment. More recent Phase II studies of carboplatin suggested a moderate level of clinical and palliative activity when it was used as a single agent. However, when carboplatin was combined with a taxane and estramustine, high response rates were observed in several recent clinical trials. In addition, a randomized trial suggested that satraplatin plus prednisone improved progression-free survival compared with prednisone alone. For patients who progressed after docetaxel, no standard options existed in the literature that was reviewed. Several preliminary reports suggested that carboplatin and oxaliplatin may have activity as second-line chemotherapy. Platinum chemotherapy drugs historically have been considered inactive in HRPC, although a review of the data suggested otherwise. Carboplatin, in particular, induced very high response rates when it was combined with estramustine and a taxane, but it also appeared to have activity in patients who progressed after docetaxel. Satraplatin plus prednisone is being investigated in a large Phase III trial as second-line chemotherapy for HRPC. Targeting neuroendocrine cells may provide a new therapeutic approach to HRPC.

show abstract

Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY

et al. 1996

View full text Add to dashboard Cite

Peptide-Hormone- And Serotonin-Immunoreactive Tumour Cells in Carcinoma of the Prostate

Cited by 142 publications

References 20 publications

Peptidylglycine ?-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate

Peptidylglycine ?-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate

Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY

Contact Info

Product

Resources

About